Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
The EMBO Journal|November 11, 2010
CAMP (C13orf8, ZNF828) is a novel regulator of kinetochore-microtubule attachmentGo Itoh, Shin-ichiro Kanno, Kazuhiko S K Uchida, et al.
Thoracic Cancer|December 14, 2021
Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancerTakashi Ito, Hiromi Nagashima, Masachika Akiyama, et al.
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|February 10, 2009
[A case of Lambert-Eaton myasthenic syndrome with small cell lung cancer, treated with 3,4-diaminopyridine]Kumi Uekita, Takashi Ishida, Satoko Sekine, et al.
Japanese Journal of Clinical Oncology|September 23, 2024
Phase II study of carboplatin plus weekly paclitaxel with bevacizumab for non-squamous, non-small cell lung cancer with idiopathic interstitial pneumonia (Hanshin Cancer Group IP002)Nobuyuki Katakami, Kazuma Nagata, Akiyoshi Nakakura, et al.
Bioorganic & Medicinal Chemistry Letters|February 4, 2012
Hit to lead SAR study on benzoxazole derivatives for an NPY Y5 antagonistNaoki Omori, Naoki Kouyama, Akira Yukimasa, et al.
Biomedicines|September 28, 2023
A Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and SafetyTatsuro Fukuhara, Kazuhiro Imai, Taku Nakagawa, et al.
Anticancer Research|November 1, 2023
Multi-gene Liquid Biopsy to Detect Resistance to First-line Osimertinib in Patients With <i>EGFR</i>-mutated Lung AdenocarcinomaShin Ito, Kyoji Tsurumi, Norihisa Shindo, et al.
Lung Cancer (Amsterdam, Netherlands)|November 22, 2019
Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203Yoko Tsukita, Akira Inoue, Shunichi Sugawara, et al.
International Journal of Clinical Oncology|November 13, 2020
Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302Yosuke Kawashima, Toshiyuki Harada, Yuka Fujita, et al.
European Journal of Cancer (Oxford, England : 1990)|April 4, 2021
Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trialKentaro Tanaka, Hajime Asahina, Junji Kishimoto, et al.
Pageof 7